Compare CZWI & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | GALT |
|---|---|---|
| Founded | 1938 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.5M | 199.2M |
| IPO Year | 2006 | 2008 |
| Metric | CZWI | GALT |
|---|---|---|
| Price | $21.38 | $2.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 13.3K | ★ 354.8K |
| Earning Date | 04-27-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | 8.96 | ★ 36.84 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $9.42 | N/A |
| P/E Ratio | $51.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.15 | $1.27 |
| 52 Week High | $22.62 | $7.13 |
| Indicator | CZWI | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 49.52 |
| Support Level | $20.22 | $2.09 |
| Resistance Level | $21.75 | $2.60 |
| Average True Range (ATR) | 0.57 | 0.23 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 68.55 | 32.69 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short - term investments; and funds provided from operations.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.